Overview
Finland medical device maker's Q1 revenue fell 17% yr/yr on lower Devices and Software sales
Company cited timing effects and U.S. reimbursement uncertainty for revenue decline
Outlook
Optomed expects full-year 2026 revenue to grow compared to 2025
Result Drivers
DEVICES SEGMENT WEAKNESS - Devices revenue declined due to timing effects and U.S. reimbursement uncertainty, which led major customers to postpone purchases
SOFTWARE SEGMENT TIMING - Software revenue fell modestly, mainly due to timing effects of various software deliveries
Company press release: ID:nWkr8gxDjf
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-EUR 0.05
Q1 EBITDA
-EUR 701,000
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Optomed Oyj is €3.80, about 61.7% above its May 5 closing price of €2.35
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
